Siirry pääsisältöön
Käyttämääsi selainta ei enää tueta – lue lisää.

High Tide

Ylin-
Alin-
Vaihto-
2026 Q3 - tulosraportti
6 päivää sitten

Tarjoustasot

Määrä
Osto
-
Myynti
Määrä
-

Viimeisimmät kaupat

AikaHintaMääräOstajaMyyjä
----

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Rahastot ja ETF:t, joilla on osaketta

Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.

Asiakkaat katsoivat myös

Yhtiötapahtumat

Datan lähde: Quartr
Seuraava tapahtuma
2026 Q4 - tulosraportti
29.1.2027
Menneet tapahtumat
2026 Q3 - tulosraportti
15.9.
2026 Q2 - tulosraportti
16.6.
2026 Q1 - tulosraportti
18.3.
2025 Q4 - tulosraportti
30.1.
2025 Q3 - tulosraportti
16.9.2025

Uutiset

Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Foorumi

Liity keskusteluun Nordnet Socialissa
Kirjaudu
  • 31.8.
    ·
    Now 232 stores. 15 in pipeline according to today's news. Remexian grows 33% q/q and 60% y/y and this is before planned acquisition in UK. Medical cannabis in Europe is expected to grow by 22% per year. This company looks set to beat that by a wide margin. It looks like they will double revenue every 24 months for a few years ahead, more or less. Schedule 3 should go through this winter and trigger institutional inflow. Q1 2027 it will be decided if the CBD pilot in USA goes through. Hiti has 2 such operations there, 500USD per patient and millions of potential customers. An operation that has been written down to 0, so a revaluation should come. 6-7 analysts follow the company, all give more or less strong buy ratings. Whoever takes the time to dig into this company will understand that it is a hidden gem in a hated sector that is becoming respectable. I believe Altria will buy up this gem because their revenue is declining and they need new revenue streams, they are already on their radar because they own Cronos which has lent money to Hiti previously. Phillip morrris and Couche tard also want into this market and probably don't want Altria to get a head start. So I potentially see a bidding war in the cards. The Elite membership grows 84% y/y and these members pay 35CAD per year, so they are loyal and only shop there for the discounts. Moats in the companies that not many know about are Cabanalytics, data that all growers are forced to acquire so they don't over or underproduce. It is a powerful moat with 90% margins, same with Elite. I usually advocate diversification when dealing with stocks, used to have a portfolio with about 15 holdings. But after spending 2 years and hundreds of hours researching this company, I have sold everything and gone all in on this company. The stock should go up 200% just to reach a normal valuation. P/S ratio is about 0.35. This is not a tiny company, 2000 employees. The CEO is super sharp and there are a bunch of interviews on YouTube. The company has gone from 3% market share in the retail segment to 12% in about 5 years. Sells 1.9 times more per store than competitors, stated in their presentation on the website. Surely forgotten something, but whoever takes the time to dig into this company will understand that it is truly skewed undervalued.
  • 4.8.
    ·
    Positive profit warning today, sold 30% more in Germany than previous guidance
  • 16.6.
    ·
    228 stores in Canada and 1 in Germany. The new acquisition Remexian is growing rapidly with good margins. Cabanalyticks and the Elite membership contribute with margins well over 90%. Shows positive net income, hence the strong share price reaction after the report. They were profitable before as well via free cash flow. But by expanding and using capex and not showing tax on the bottom line means they didn't have to show profits, so it's a smart way to grow cheaper. Several insider purchases occurred about a month ago. Everything is ticking along as it should and more. Hopefully, Scheduall 3 will soon go through and a flood of money will come into the sector.
  • 18.12.2025
    ·
    218 Stores in Canada, the first one recently opened in Germany. The acquisition of Remexian will be visible in the next quarterly report. The company is investigating whether they can license out stores in the USA without violating rules against Nasdaq, where they are listed. The day it becomes legal, they have the option to buy back the companies and already have an existing foothold. Hiti delivers every quarter and has done so for several years now. Best bet in the sector long-term.
  • 21.10.2025
    ·
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, ​​eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Tuotteita joiden kohde-etuutena tämä arvopaperi

Välittäjätilasto

Dataa ei löytynyt
2026 Q3 - tulosraportti
6 päivää sitten

Uutiset

Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Foorumi

Liity keskusteluun Nordnet Socialissa
Kirjaudu
  • 31.8.
    ·
    Now 232 stores. 15 in pipeline according to today's news. Remexian grows 33% q/q and 60% y/y and this is before planned acquisition in UK. Medical cannabis in Europe is expected to grow by 22% per year. This company looks set to beat that by a wide margin. It looks like they will double revenue every 24 months for a few years ahead, more or less. Schedule 3 should go through this winter and trigger institutional inflow. Q1 2027 it will be decided if the CBD pilot in USA goes through. Hiti has 2 such operations there, 500USD per patient and millions of potential customers. An operation that has been written down to 0, so a revaluation should come. 6-7 analysts follow the company, all give more or less strong buy ratings. Whoever takes the time to dig into this company will understand that it is a hidden gem in a hated sector that is becoming respectable. I believe Altria will buy up this gem because their revenue is declining and they need new revenue streams, they are already on their radar because they own Cronos which has lent money to Hiti previously. Phillip morrris and Couche tard also want into this market and probably don't want Altria to get a head start. So I potentially see a bidding war in the cards. The Elite membership grows 84% y/y and these members pay 35CAD per year, so they are loyal and only shop there for the discounts. Moats in the companies that not many know about are Cabanalytics, data that all growers are forced to acquire so they don't over or underproduce. It is a powerful moat with 90% margins, same with Elite. I usually advocate diversification when dealing with stocks, used to have a portfolio with about 15 holdings. But after spending 2 years and hundreds of hours researching this company, I have sold everything and gone all in on this company. The stock should go up 200% just to reach a normal valuation. P/S ratio is about 0.35. This is not a tiny company, 2000 employees. The CEO is super sharp and there are a bunch of interviews on YouTube. The company has gone from 3% market share in the retail segment to 12% in about 5 years. Sells 1.9 times more per store than competitors, stated in their presentation on the website. Surely forgotten something, but whoever takes the time to dig into this company will understand that it is truly skewed undervalued.
  • 4.8.
    ·
    Positive profit warning today, sold 30% more in Germany than previous guidance
  • 16.6.
    ·
    228 stores in Canada and 1 in Germany. The new acquisition Remexian is growing rapidly with good margins. Cabanalyticks and the Elite membership contribute with margins well over 90%. Shows positive net income, hence the strong share price reaction after the report. They were profitable before as well via free cash flow. But by expanding and using capex and not showing tax on the bottom line means they didn't have to show profits, so it's a smart way to grow cheaper. Several insider purchases occurred about a month ago. Everything is ticking along as it should and more. Hopefully, Scheduall 3 will soon go through and a flood of money will come into the sector.
  • 18.12.2025
    ·
    218 Stores in Canada, the first one recently opened in Germany. The acquisition of Remexian will be visible in the next quarterly report. The company is investigating whether they can license out stores in the USA without violating rules against Nasdaq, where they are listed. The day it becomes legal, they have the option to buy back the companies and already have an existing foothold. Hiti delivers every quarter and has done so for several years now. Best bet in the sector long-term.
  • 21.10.2025
    ·
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, ​​eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Tarjoustasot

Määrä
Osto
-
Myynti
Määrä
-

Viimeisimmät kaupat

AikaHintaMääräOstajaMyyjä
----

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Rahastot ja ETF:t, joilla on osaketta

Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.

Asiakkaat katsoivat myös

Yhtiötapahtumat

Datan lähde: Quartr
Seuraava tapahtuma
2026 Q4 - tulosraportti
29.1.2027
Menneet tapahtumat
2026 Q3 - tulosraportti
15.9.
2026 Q2 - tulosraportti
16.6.
2026 Q1 - tulosraportti
18.3.
2025 Q4 - tulosraportti
30.1.
2025 Q3 - tulosraportti
16.9.2025

Tuotteita joiden kohde-etuutena tämä arvopaperi

Välittäjätilasto

Dataa ei löytynyt
2026 Q3 - tulosraportti
6 päivää sitten

Uutiset

Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Yhtiötapahtumat

Datan lähde: Quartr
Seuraava tapahtuma
2026 Q4 - tulosraportti
29.1.2027
Menneet tapahtumat
2026 Q3 - tulosraportti
15.9.
2026 Q2 - tulosraportti
16.6.
2026 Q1 - tulosraportti
18.3.
2025 Q4 - tulosraportti
30.1.
2025 Q3 - tulosraportti
16.9.2025

Tuotteita joiden kohde-etuutena tämä arvopaperi

Foorumi

Liity keskusteluun Nordnet Socialissa
Kirjaudu
  • 31.8.
    ·
    Now 232 stores. 15 in pipeline according to today's news. Remexian grows 33% q/q and 60% y/y and this is before planned acquisition in UK. Medical cannabis in Europe is expected to grow by 22% per year. This company looks set to beat that by a wide margin. It looks like they will double revenue every 24 months for a few years ahead, more or less. Schedule 3 should go through this winter and trigger institutional inflow. Q1 2027 it will be decided if the CBD pilot in USA goes through. Hiti has 2 such operations there, 500USD per patient and millions of potential customers. An operation that has been written down to 0, so a revaluation should come. 6-7 analysts follow the company, all give more or less strong buy ratings. Whoever takes the time to dig into this company will understand that it is a hidden gem in a hated sector that is becoming respectable. I believe Altria will buy up this gem because their revenue is declining and they need new revenue streams, they are already on their radar because they own Cronos which has lent money to Hiti previously. Phillip morrris and Couche tard also want into this market and probably don't want Altria to get a head start. So I potentially see a bidding war in the cards. The Elite membership grows 84% y/y and these members pay 35CAD per year, so they are loyal and only shop there for the discounts. Moats in the companies that not many know about are Cabanalytics, data that all growers are forced to acquire so they don't over or underproduce. It is a powerful moat with 90% margins, same with Elite. I usually advocate diversification when dealing with stocks, used to have a portfolio with about 15 holdings. But after spending 2 years and hundreds of hours researching this company, I have sold everything and gone all in on this company. The stock should go up 200% just to reach a normal valuation. P/S ratio is about 0.35. This is not a tiny company, 2000 employees. The CEO is super sharp and there are a bunch of interviews on YouTube. The company has gone from 3% market share in the retail segment to 12% in about 5 years. Sells 1.9 times more per store than competitors, stated in their presentation on the website. Surely forgotten something, but whoever takes the time to dig into this company will understand that it is truly skewed undervalued.
  • 4.8.
    ·
    Positive profit warning today, sold 30% more in Germany than previous guidance
  • 16.6.
    ·
    228 stores in Canada and 1 in Germany. The new acquisition Remexian is growing rapidly with good margins. Cabanalyticks and the Elite membership contribute with margins well over 90%. Shows positive net income, hence the strong share price reaction after the report. They were profitable before as well via free cash flow. But by expanding and using capex and not showing tax on the bottom line means they didn't have to show profits, so it's a smart way to grow cheaper. Several insider purchases occurred about a month ago. Everything is ticking along as it should and more. Hopefully, Scheduall 3 will soon go through and a flood of money will come into the sector.
  • 18.12.2025
    ·
    218 Stores in Canada, the first one recently opened in Germany. The acquisition of Remexian will be visible in the next quarterly report. The company is investigating whether they can license out stores in the USA without violating rules against Nasdaq, where they are listed. The day it becomes legal, they have the option to buy back the companies and already have an existing foothold. Hiti delivers every quarter and has done so for several years now. Best bet in the sector long-term.
  • 21.10.2025
    ·
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, ​​eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Tarjoustasot

Määrä
Osto
-
Myynti
Määrä
-

Viimeisimmät kaupat

AikaHintaMääräOstajaMyyjä
----

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Rahastot ja ETF:t, joilla on osaketta

Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.

Asiakkaat katsoivat myös

Välittäjätilasto

Dataa ei löytynyt